Year: 2020
Type: article
Abstract: PURPOSE OF REVIEW: To provide an evidence-based approach to the use of therapies that are prescribed to improve the natural history of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)-a rare disease. RECENT FINDINGS: All 41 articles on the clinical outcome of disease-modifying therapy for HAM/TSP were included in a systematic review by members of the International Retrovirology Association; we report here the consensus assessment and recommendations. The quality of available evidence is low, based for the most part on observational studies, with only 1 double-masked placebo-controlled randomized trial. SUMMARY: There is evidence to support the use of both high-dose pulsed methyl prednisolone for induction and low-dose (5 mg) oral prednisolone as maintenance therapy for progressive disease. There is no evidence to support the use of antiretroviral therapy. There is insufficient evidence to support the use of interferon-α as a first-line therapy.
Source: Neurology Clinical Practice
Institutions: Universidade Federal do Rio de Janeiro, National Institutes of Health, St. Marianna University School of Medicine, Universidade de São Paulo, Instituto de Infectologia Emílio Ribas, Instituto Nacional de Infectologia Evandro Chagas, Imperial College London, Fundação Oswaldo Cruz, Universidade Federal do Estado do Rio de Janeiro, Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Funders: Wellcome Trust, Medical Research Council
OpenAlex ID: W3012056254
